QT Imaging Holdings (QTI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Jun, 2026Executive summary
Annual meeting scheduled for July 28, 2026, to be held virtually, with record date June 23, 2026.
2025 revenue reached $18.9 million, a 288% increase from 2024, with gross margin at 45%.
Net loss for 2025 was $21.1 million, impacted by non-cash expenses and fair value adjustments.
Financial position strengthened via $18.2 million private placement and $5 million debt repayment.
Uplisted to Nasdaq Capital Market in January 2026 after a 3:1 reverse stock split.
Expanded international distribution agreements in Saudi Arabia and UAE.
Voting matters and shareholder proposals
Election of two Class II directors to serve until 2029.
Ratification of BPM LLP as independent registered public accounting firm for fiscal 2026.
Approval of amendment to 2024 Equity Incentive Plan to increase reserved shares by 550,900.
Board recommends voting FOR all proposals.
Shareholder proposals and nominations for 2027 annual meeting must comply with advance notice and SEC rules.
Board of directors and corporate governance
Board consists of seven members, classified into three classes with staggered three-year terms.
Majority of directors are independent per Nasdaq standards.
Board leadership is separated between Chairman and CEO roles.
Three standing committees: Audit, Compensation, and Nominating and Corporate Governance.
Code of Business Conduct and Ethics and Corporate Governance Guidelines adopted and available online.
Latest events from QT Imaging Holdings
- High-resolution, scalable breast imaging platform drives rapid growth and global adoption.QTI
Investor presentation - Q2 2026 revenue jumped 103% to $7.4M, but net loss widened; 2026 outlook reaffirmed.QTI
Q2 2026 - All proposals, including director elections and equity plan amendment, passed by large margins.QTI
AGM 2026 - Shareholders will vote on director elections, auditor ratification, and an expanded equity incentive plan.QTI
Proxy filing - FDA-cleared 3D breast imaging platform drives rapid growth with AI and global partnerships.QTI
Investor presentation - Q1 2026 revenue rose 133% to $6.5M, with narrowed losses and ongoing risks from customer and region.QTI
Q1 2026 - Q2 2024 revenue hit $1.7M with 51% margin; net loss widened to $6.4M amid higher costs.QTI
Q2 2024 - $2.56M PIPE financing and $1.0M Q3 revenue support liquidity amid ongoing commercialization.QTI
Q3 2024 - Q3 2025 revenue rose 339% to $4.2M; 2026 revenue outlook raised to $39M.QTI
Q3 2025